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Abstract
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important factor in the etiology of familial
hypercholesterolemia (FH) and is also an attractive therapeutic target to reduce low density lipoprotein (LDL) cholesterol.
PCSK9 accelerates the degradation of hepatic low density lipoprotein receptor (LDLR) and low levels of hepatic PCSK9
activity are associated with reduced levels of circulating LDL-cholesterol.
Methodology/Principal Findings: The present study presents the first evidence for the efficacy of a locked nucleic acid
(LNA) antisense oligonucleotide (LNA ASO) that targets both human and mouse PCSK9. We employed human hepatocytes
derived cell lines HepG2 and HuH7 and a pancreatic mouse b-TC3 cell line known to express high endogenous levels of
PCSK9. LNA ASO efficiently reduced the mRNA and protein levels of PCSK9 with a concomitant increase in LDLR protein
levels after transfection in these cells. In vivo efficacy of LNA ASO was further investigated in mice by tail vein intravenous
administration of LNA ASO in saline solution. The level of PCSK9 mRNA was reduced by ,60%, an effect lasting more than
16 days. Hepatic LDLR protein levels were significantly up-regulated by 2.5–3 folds for at least 8 days and ,2 fold for 16
days. Finally, measurement of liver alanine aminotransferase (ALT) levels revealed that long term LNA ASO treatment (7
weeks) does not cause hepatotoxicity.
Conclusion/Significance: LNA-mediated PCSK9 mRNA inhibition displayed potent reduction of PCSK9 in cell lines and
mouse liver. Our data clearly revealed the efficacy and safety of LNA ASO in reducing PCSK9 levels, an approach that is now
ready for testing in primates. The major significance and take home message of this work is the development of a novel and
promising approach for human therapeutic intervention of the PCSK9 pathway and hence for reducing some of the
cardiovascular risk factors associated with the metabolic syndrome.
Citation: Gupta N, Fisker N, Asselin M-C, Lindholm M, Rosenbohm C, et al. (2010) A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and
Enhances LDLR Expression In Vitro and In Vivo. PLoS ONE 5(5): e10682. doi:10.1371/journal.pone.0010682
Editor: Sumitra Deb, Virginia Commonwealth University, United States of America
Received February 10, 2010; Accepted April 25, 2010; Published May 17, 2010
Copyright:  2010 Gupta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Canadian Institutes of Health Research grant MOP 36496 and a team grant CTP 82946. These funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition, this project was partially funded by Santaris Pharma
A/S, allowing a collaborative effort in which Santaris Pharma was co-author in this study. The design of the LNA and its synthesis and mouse work was donea t
Santaris, and the extensive cell biology work was done at the IRCM. The decision to publish and prepration of the manuscript was by common agreement and
effort between the IRCM and Santaris.
Competing Interests: NGS, NG and M-CA are employees of the IRCM. NF, ML, CR, JE and EMS are employees of Santaris Pharmna A/S. This does not alter their
adherence to all the PLOS ONE policies, including sharing data and materials.
* E-mail: seidahn@ircm.qc.ca
. These authors contributed equally to this work.
" These authors also contributed equally to this work.
Introduction
In 2003, the proprotein convertase subtilisin/kexin-9 (PCSK9; a
692 amino acid protein) was discovered [1] and its high expression
levels in liver and small intestine and the chromosomal localization
of its gene (,22 kb PCSK9) on 1p32.3, suggested a possible
relationship to cholesterol metabolism [1]. Indeed, Abifadel et al.
reported several gain of function variants of human PCSK9 that
are associated with familial hypercholesterolemia (FH) [2]. PCSK9
is thought to accelerate the degradation of hepatic low density
lipoprotein receptor (LDLR) [3–5] in endosomes/lysosomes [6] by
direct binding of the catalytic subunit of PCSK9 to the EGF-A
domain of the LDLR [7,8]. PCSK9 over-expression in cell lines
and direct intravenous injection of the protein to mice were shown
to reduce LDLR levels and increase plasma LDL-cholesterol
(LDL-C) [4,5,9,10]. Conversely, loss of function variants of human
PCSK9 or inactivation of the mouse Pcsk9 gene, lead to decreased
plasma LDL-C [11,12], and in mice to increased hepatic LDLR
protein [13,14].
More than 50 amino acid variants of PCSK9 (see http://www.
ucl.ac.uk/ldlr/LOVDv.1.1.0/) are known so far and some have
been clearly shown to affect plasma cholesterol levels in humans
[12,15,16]. These changes are classified as ‘‘gain-of-function’’
(GOF) mutations when they are associated with high levels of
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ated with low LDL-C. GOF mutations result in mild to severe
hypercholesterolemia. In the most severe Anglo-Saxon mutation,
D374Y, total cholesterol (TC) values reach as high as 13.1 mmol/
L [17,18], which are .4 fold higher than normal. The onset of
coronary artery disease (CAD) in patients with D374Y may be 10
years sooner than in heterozygous FH patients with severe LDLR
mutations [19]. On the other hand, two nonsense heterozygote
LOF mutations were associated with a 28% reduction of plasma
LDL-C and 88% reduction in the frequency of coronary events
[20]. Amazingly, complete loss of PCSK9 function has been
reported in two adult women, exhibiting a strikingly low plasma
level of LDL-C (,0.4 mmol/L) [15,21], and no immunodetect-
able circulating PCSK9 [15]. These findings support the
hypothesis that higher levels and/or activity of plasma PCSK9
increase the levels of circulating LDL-C and TC, suggesting that
long-term lowering of PCSK9 might be beneficial in reducing the
incidence of CAD, and hence PCSK9 is an attractive target for
treatment of dyslipidemia [22–24].
While the mechanism by which PCSK9 regulates LDLR
degradation is not fully resolved, it seems to involve both
intracellular and extracellular pathways [4,25]. We recently
reported evidence that the intracellular pathway of LDLR
degradation by PCSK9 exists in various cell types and that it is
distinct from the extracellular one [26].
Targeting the extracellular pathway has recently been effec-
tively achieved in cynomolgus monkeys following intravenous
injection of a specific monoclonal antibody that interferes with the
PCSK9;EGF-A interaction, with PCSK9 and LDL-C lowering
effect lasting more than 2-weeks [27]. Another approach that
would affect both the intra- and extracellular pathways would
involve the use of antisense oligonucleotides to reduce the levels of
PCSK9 transcripts. The first report employing this approach used
repeated intraperitoneal injections (100 mg/kg weekly) of a water
soluble chimeric 29-O-methoxyethyl phosphorothioate 20-mer
antisense oligonucleotide (ASO) in high fat diet-fed mice for 6-
weeks. This resulted in ,90% drop of PCSK9 mRNA in liver,
reduced circulating total cholesterol and LDL-C by 53% and
38%, respectively, and a 2-fold increase in the level of hepatic
LDLR. However, HDL-C was also reduced with 54% [28].
The second approach utilized liposome encapsulated small
interfering RNAs siRNAs as injectable lipidoid nanoparticles
(LNP) [29]. Notable, formulation is necessary and it is mechanis-
tically distinct from antisense oligonucleotides. The effects of
PCSK9 silencing lasted for 3-weeks after a single intravenous
administration, and led to a 50–70% reduction in PCSK9 mRNA
in mouse and rat liver and significantly lowered plasma LDL-C in
cynomolgus monkeys, without affecting high density lipoprotein-
cholesterol (HDL-C) or triglycerides [29].
The final strategy employed in this study, is to use high affinity,
single stranded, unformulated, 12–16 nucleotide short locked
nucleic acid (LNA) modified gap-mer antisense oligonucleotides.
Such molecules have been shown to potently and safely inhibit
both mRNA and miRNA targets in mouse [30] and non-human
primate [31,32] models, and several different LNA drugs are
currently in clinical trials against cancer and infectious diseases.
In the present study, we present the first evidence for the
efficacy of a short LNA antisense oligonucleotide (ASO) that
targets both human and mouse PCSK9. We employed human
hepatocytes derived cell lines HepG2 and HuH7 and a pancreatic
mouse bTC3 cell line known to express high endogenous levels of
PCSK9 [1]. Transfection of these cells with LNA ASO efficiently
reduces the mRNA and protein levels of PCSK9 with a
concomitant increase in cell surface LDLR protein levels. In vivo
efficacy of LNA ASO was further investigated in mice by
intravenous (i.v.) administration of the unformulated LNA ASO
in saline solution. The level of PCSK9 mRNA was reduced by
,60%, an effect lasting more than 16 days. The estimated ED50
was 9 mg/kg. Hepatic LDLR protein levels were significantly up-
regulated 2.5–3 fold for at least 8 days and ,2 fold for 16 days.
Materials and Methods
Ethics Statement
All experiments were performed according to the principles
stated in the Danish law on animal experiments, and were
approved by the Danish National Committee for Animal
Experiments, Ministry of Justice, Denmark (permit number
2007/561-1292).
Oligonucleotide design and synthesis
The LNA antisense oligonucleotide (LNA ASO) complementary
to the human and mouse PCSK9 mRNA (accession # NM174936
and NM153565) was designed as described previously [33]. It is a
13-nucleotide long gapmer with the following sequence:
GTctgtggaaGCG (uppercase LNA, lowercase DNA) and phos-
phorothioate internucleoside linkages. The oligonucleotides were
synthesized using standard phosphoramidite protocols on an
A ¨KTA Oligopilot (GE Healthcare) at 130 mmol to 8 mmol scales
employing custom made polystyrene primer supports. The DNA
monomers were obtained from Proligo (Sigma-Aldrich) and the
LNA monomers and solid support were produced by Santaris
Pharma (commercially available from Exiqon, Denmark). After
synthesis, the oligonucleotides were cleaved from the support using
aqueous ammonia at 65uC overnight. The oligonucleotides were
purified by ion exchange and desalted using a Millipore-
membrane and were finally characterized by LC-MS (Reverse
phase and ESI-MS).
Cell cultures and transfections
Hepatic HepG2 cells (American Type Culture Collection,
Manassas, VA) were maintained in complete medium consisting of
EMEM (Invitrogen, Burlington, Ontario, Canada), 2 mM Gluta-
MAX (Invitrogen), 16NEAA (Invitrogen), and 10% fetal bovine
serum at 37uC, 5% CO2. HuH7 cells (a gift from Francois Jean,
University of British Columbia) were routinely cultivated in
Dulbecco’s modified Eagle’s medium plus 10% FBS. Mouse
pancreatic insulinoma b-TC3 cells (a gift from Doug Hanahan,
University of California San Francisco) were also maintained in
Dulbecco’s modified Eagle’s medium with 10% FBS.
HepG2 transfection in 6-well plates. At the time of
transfection 250 ml of a mix of 10.2 mg/ml Lipofectamine 2000
(Invitrogen) in OptiMEM I (Invitrogen) was added to each empty
well in a 6-well plate and left at room temperature for 5 min. Next,
a 250 ml mix of oligonucleotide at appropriate concentration and
OptiMEM I was added to each well gently mixed and left at room
temperature for 15 min. Finally a 1 ml suspension of 6.5610
5
HepG2 cells in complete media was added to each well and cells
were incubated for 4 h at 37uC, 5% CO2 (final concentration:
1.7 mg/ml of Lipofectamine 2000, 0–25 nM of LNA
oligonucleotide). After incubation the cells were washed in 2 ml
OptiMEM I and added fresh complete media and incubated at
37uC, 5% CO2 until harvested.
HuH7 and b-TC3 transfections in 6-well plates. Cells
were seeded one day before transfection at a density of 2.5610
5
cells per well in 6-well plates. At 60–70% confluence, cells were
transfected with oligonucleotides diluted in sterile water at final
concentrations varying from 0–25 nM. In mock control cells,
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transfection cells in each well were first washed in 2 ml
Dulbecco’s Phosphate Buffered Saline (PBS) brought to room
temperature and afterwards added 1.2 ml of a 6.3 mg/ml
Lipofectamine 2000 in OptiMEM I solution. The cells were left
for 7 minute at room temperature. Next 300 ml of LNA
oligonucleotides at varying concentrations dissolved in
OptiMEM I were added and the cells were incubated for 4 h at
37uC, 5% CO2 (final concentration: 5 mg/ml of Lipofectamine
2000, 0–25 nM of LNA oligonucleotide). After incubation the cells
were washed in 2 ml PBS and added fresh complete media and
incubated at 37uC, 5% CO2 until harvested.
For total RNA extraction, cells were harvested 24–48 h post
transfection and for Western blot, transfected cells were first
incubated in complete media for 2 days, followed with incubation
for overnight in condition media (medium without FBS). The next
day, media were collected and cells lysed.
In vivo study in mice
Female NMRI mice (Taconic, Denmark) were used in all
studies and were fed ad libitum (diet: altromin no 1324, 4 wt % fat,
Brogaarden, Denmark). The animals were subjected to a 12 h
light cycle, temperature of 2162uC and a relative humidity of
55610%.
The oligonucleotide was dissolved in physiological saline
solution, which also served as control and was administered
intravenously (i.v.) in the tail vein. The mice were dosed either a
single injection of 5–40 mg/kg or weekly injections of 5 mg/kg.
At sacrifice, the mice were anesthetized (70% CO2/30% O2)
before blood sampling and cervical dislocation. Liver samples were
collected both in RNA-later (Sigma-Aldrich, Denmark) and snap-
frozen in liquid nitrogen. All experiments were performed
according to the principles stated in the Danish law on animal
experiments, and were approved by the Danish National
Committee for Animal Experiments, Ministry of Justice, Den-
mark.
RNA preparation and cDNA synthesis
Cells were washed three times with PBS and incubated with
Trizol reagent (Invitrogen). Total RNA was extracted according to
the manufacturer’s instructions and resuspended in 20–30 mlo f
RNase-DNase free water. Isolated RNA integrity was electropho-
retically verified by ethidium bromide staining of agarose gel and
optical density (OD), with an OD260/OD280 average absorption
ratio of 1.8 to 2.0. Typically, 250 ng of total RNA were used for
cDNA synthesis in a total volume of 20 ml using SuperScript II
reverse transcriptase, 25 mg/mL oligo(dT) 12–18 mer, 0.5 mmol/
L2 9-deoxynucleoside 59-triphosphates, and 40 U of RNaseOUT
(all products from Invitrogen).
From tissue homogenates, total RNA was extracted using the
RNeasy mini kit (Qiagen, Demark). cDNA of total RNA extracted
from mice tissues, was synthesized by reverse transcription using
random decamers, 0.5 mg total RNA, and M-MLV RT (Ambion,
Denmark), according to manufacturer’s instructions.
Quantitative PCR
Quantitative PCR (QPCR) was performed as previously
described [26,34,35]. For each cell line, one to three RNA
samples were analyzed at least twice in triplicates. Specific primers
were used for the simultaneous amplification of the normalizing
cDNA for ribosomal protein S14 or S16, and the cDNA for
PCSK9, LDLR and HMGCoAR, as reported [14,26,34].
For quantification of PCSK9 and LDLR mRNAs in mouse tissues,
TaqMan Gene Expression Assays (PCSK9 #Mm00463738_m1,
LDLR #Mm00440169_m1, Apobec #:Mm00482894_m1 and
GAPDH #4352339E) and a 7500 Fast real-time PCR instrument
(Applied Biosystems, Denmark) was used. Data were analyzed with
the 7500 Fast System software. Quantified mRNA levels were
normalized to GAPDH and presented relative to saline control.
Western blot analysis
Cells were washed three times in phosphate-buffered saline
and lysed in RIPA buffer (50 mM Tris/HCl, pH 8.0, 1% (v/v)
Nonidet P40, 0.5% sodium deoxycholate, 150 mM NaCl and
0.1% (v/v) SDS) with a Complete Protease Inhibitor Mixture
(Roche Applied Science, Laval, Quebec, Canada). Proteins were
separated by SDS-polyacrylamide gel electrophoresis (8% gels)
and blotted on HyBond nitrocellulose membranes (GE Health-
care, Baie d’Urfe, Quebec, Canada), which were blocked for 1 h
in TBS-T (50 mM Tris- HCl, pH 7.5, 150 mM NaCl, 0.1%
Tween 20) containing 5% non-fat dry milk. Afterward,
membranes were incubated for 3 h at room temperature in
1% non-fat milk with the respective antibodies: hPCSK9
(1:2,500), hLDLR (1:1,000) (R&D, Minneapolis, MN) and b-
Actin (1:5,000) (Sigma, Oakville, Ontario, Canada). Appropriate
horseradish peroxidase-conjugated antibodies (1:10,000; Sigma)
were used for detection with enhanced chemiluminescence using
the ECL Western blotting substrate (Pierce, Nepean, Ontario,
Canada).
Western blot analysis of LDLR in tissues was performed as
follows: Snap frozen liver tissue samples (approximately 30 mg)
were defrosted and homogenized in 300 ml T-per Tissue Protein
Extraction buffer, supplemented with Halt Protease inhibitor
cocktail (Pierce, Denmark). Total protein concentrations were
determined with BCA protein assay kit (Pierce, Denmark) using an
albumin standard according to manufacturer’s protocol. 25 mg
total protein from each sample was prepared in 46LDS sample
buffer (Invitrogen, Denmark) loaded on a 4–12% Bis-Tris gel
(NuPAGE, Invitrogen, Denmark) and separated for 2 h at 130 V
in MOPS buffer (Invitrogen, Denmark). Proteins were blotted
onto a PVDF membrane using an XCell II Blot Module
(Invitrogen, Denmark) according to standard protocol. The
membrane was blocked in 5% skimmed milk powder in 16PBS
over night. The membrane was there after incubated overnight in
a blocking solution including primary antibodies (polyclonal goat-
anti-mouse-LDLR antibody 1:1000 dilution, R&D Systems,
Denmark and monoclonal Mouse-anti-tubulin antibody, 1:2000
dilution NeoMarkers, Denmark). Subsequently the membrane was
incubated for 2 h with secondary antibodies (HRP/anti-goat
1:2000 dilution and 1:2000 HRP/anti-mouse, Dako, Denmark).
LDLR and tubulin bands were visualized using Chemilumines-
cence ECL+ detection kit (Amersham, Denmark), captured with a
VersaDoc5000 imaging system (Bio-Rad, Denmark) and quanti-
fied using Quantity One software (Bio-Rad, Denmark). LDLR
protein levels were normalized to tubulin and presented relative to
saline control.
FACS analysis
Transfected HepG2 cells were processed for flow cytometry
after 72 h of transfection. Cells were washed with buffer A (16
PBS with 7.1 ml BSA 235%, and 2.0 ml glucose 2250 mg/L)
and then stained with a mouse anti-human primary antibody
(Santa Cruz Biotechnology) for 40 min at room temperature at
dilution of 1:100. As for secondary antibody, anti-mouse
conjugated with Alexa 647 was used (1:250) for 20 minutes at
room temperature. Flow cytometry analysis was performed by BD
LSR Cytometer (BD Biosciences), and the data were analyzed
PCSK9 Silencing In Vivo
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sample, 10,000 live events were collected.
Cytotoxicity assay
The toxicity was evaluated by colorimetric Alamar blue assay
[36]. The blue colored reagent Alamar blue contains resazurin
which is reduced to a pink colored resorufin by the metabolic
mitochondrial activity of viable cells and can be quantified
colorimetrically and fluorimetrically. For assessing the cell viability,
HepG2 cells were transfected with LNA antisense oligonucleoti-
deas described above in the transfection experiment, in a 24-well
plate. After 48 h, 50 ml of Alamar blue reagent, pre-warmed at
37uC was added to each well and incubated for another 2 h. At the
end of incubation 80 ml of media containing reduced Alamar blue
dye was transferred to 96 well plate and read on Elisa plate reader
at 570 nm. Untreated cells were taken as control with 100%
viability and cells without addition of Alamar blue were used as
blank. The relative cell viability (%) compared to control cells was
calculated by [(Absorbance)sample/(Absorbance)control]6100.
Statistical analysis
Statistical analysis was performed using One-Way ANOVA
with Bonferroni’s Multiple Comparison as post test if the data
followed a Gaussian distribution. If not, the non-parametric
Kruskal Wallis test with Dunn’s Multiple Comparison was used
as a post test. Where only two groups were compared,
Student’s t-test was used for the statistical analysis. P values
of ,0.05 were considered statistical significant. GraphPad
Prism (version 4.03, GraphPad Software) was used for the
statistical analysis.
Results and Discussion
LNA induced gene-specific silencing of PCSK9 mRNA in
vitro
PCSK9 is primarily synthesized in liver, kidney and small
intestine of vertebrates, with a major expression in liver [1].
PCSK9 down-regulates the protein levels of the LDLR by
enhancement of its intracellular metabolic pathway in subcellular
acidic compartments, without affecting LDLR mRNA levels [3–5].
Many studies have shown the correlation of significant reduction in
the risk of coronary heart disease with ‘loss-of-function’ of PCSK9
[11,20]. Furthermore, Pcsk9 knock-out mice exhibit decreased
levels of circulating LDL-C, demonstrably due to a high
concentration of cell-surface hepatic LDLR [13,14]. These data
strongly suggested that inhibitors/silencers of the PCSK9-mediated
degradation of LDLR would be valuable tools to control plasma
LDL-cholesterol levels [22,24]. This hypothesis justified the testing
of LNA antisense oligonucleotides as a novel approach to diminish
the activity of PCSK9 on LDLR degradation.
LNA ASO was transfected into HepG2 and HuH7 cells and a
b-TC3 mouse insulinoma pancreatic cell line. Cells were harvested
Figure 1. Intracellular reduction of targeted PCSK9 mRNA by LNA ASO. Two human hepatic cell lines: HepG2 and HuH7 and a mouse
insulinoma b-TC3 cell line; were transfected with LNA ASO, at concentrations of 10 and 25 nM. Total RNA was extracted at two different time points-
24 h and 48 h post transfection and QPCR analysis was performed using specific primers. The levels of PCSK9 mRNA were normalized to S14 mRNA
for (A) HepG2 and (B) HuH7 cells; and (C) with S16 mRNA for b-TC3 cells.
doi:10.1371/journal.pone.0010682.g001
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polymerase chain reaction (QPCR) was then performed to assess
the decrease in PCSK9 mRNA expression, and measure its effect
on the levels of LDLR and HMG-CoA-reductase (HMGCoAR)
transcripts. As control, mock transfections were done with water
instead of LNA ASO.
As shown in Figure 1, more than 60% reduction in PCSK9
mRNA levels in human HepG2 (panel A; P,0.01), and
approximately 50% in HuH7 (panel B; P,0.02) and mouse b-
TC3 (panel C; P,0.05) cells were achieved after 24 h using either
10 or 25 nM LNA ASO. The same trend remained at 48 h post-
transfection. We did not see any significant LNA-mediated change
in the expression of LDLR mRNA in HepG2 (Figure 2A;
P,0.01), HuH7 (Figure 2B; P,0.002) or in b-TC3 (Figure 2C;
P,0.05) cells at the 48 h time point. Also, following 48h
incubation no significant change was observed in the levels of
Figure 2. Effect of LNA ASO on mRNA expression of LDLR. Human hepatic HepG2 and HuH7 and mouse insulinoma b-TC3 cells were
transfected with LNA ASO at concentrations of 10 nM and 25 nM, and the levels of LDLR mRNA analyzed by QPCR after 24 h and 48 h. The levels of
LDLR mRNA were normalized to (A and B) S14 mRNA and (C) S16 mRNA for human and mouse origin, respectively.
doi:10.1371/journal.pone.0010682.g002
Figure 3. QPCR analysis of HMGCoAR mRNA. (A) HepG2 cells and (B) b-TC3 cells transfected with 10 and 25 nM LNA ASO and analyzed at 24 h
and 48 h post-transfection. Human S14 and mouse S16 mRNAs were used for normalization.
doi:10.1371/journal.pone.0010682.g003
PCSK9 Silencing In Vivo
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TC3 cells (Figure 3B; P,0.03).
The target-specificity of the LNA ASO to PCSK9 mRNA was
reflected by the lack of effect on LDLR mRNA and by the use of a
control untargeted LNA ASO, which showed no off-target effect
on the mRNA levels of PCSK9 and LDLR in HepG2 and b-TC3
cells (Figure S1).
However, we did observe a decrease in the mRNA expression of
LDLR and HMGCoAR at 24 h post-transfection (Figures 2 and 3
and S1), likely due to the down-regulation of SREBP activity in
presence of lipids/sterols present in the lipofectamine reagent, as
previously reported [26]. However, this effect was gone after 48h,
where mRNA levels of LDLR and HMGCoAR returned to
control levels.
We conclude that in the three cell lines used LNA ASO
significantly inhibits the expression of human (HepG2 and HuH7
cells) and mouse (b-TC3 cells) PCSK9 mRNA, with no observable
effects on the mRNA expression levels of LDLR and HMGCoAR.
LNA ASO induced silencing of PCSK9 enhances
expression of LDLR protein
Western blot analysis was done in HepG2 cells to test the effect
of LNA-based silencing of PCSK9 mRNA on the protein level of
PCSK9, and thus in turn on LDLR protein. For this experiment,
HepG2 cells were transfected with 5, 10 and 25 nM LNA ASO,
incubated for a total of 72h, and the conditioned medium
analyzed was that of the last 18h. In Figure 4A, cell lysates were
probed by Western blot for endogenous levels of PCSK9 and
LDLR proteins in the presence and absence of LNA ASO. In
panel B, The effect of the LNA ASO on the levels of secreted
PCSK9 in the conditioned medium were also probed (Figure 4B).
The loading control b-actin was constant in all samples. In
presence of 10 and 25 nM LNA ASO we observed a decrease of
,70–80% in endogenous cellular PCSK9 (panel A, lanes 3 and 4)
and ,50–70% in secreted PCSK9 levels (panel B, lanes 3 and 4),
as compared to mock-transfected samples. This decrease in
protein expression of PCSK9 was associated with a ,3-fold
increase in the levels of LDLR protein (upper panel, Figure 4A).
One of the major functions of PCSK9 is its ability to reduce the
protein level of hepatic LDLR, by dragging the latter towards
endosomes/lysosomes for degradation [3–5]. The present studies
support such a role, since the LNA ASO that inhibits expression of
PCSK9, results in a concomitant increase of total intracellular
protein levels of the LDLR, without affecting its mRNA levels.
FACS analysis of LDLR surface expression in HepG2 cells
To further establish the knock-down efficiency of the LNA ASO
of PCSK9 mRNA, flow cytometric analysis (FACS) of HepG2 cells
transfected with the LNA ASO was carried out in order to verify
whether the observed increased total amounts of LDLR also
reflects higher cell-surface levels.
For FACS, HepG2 cells were transfected and incubated for 72h
as described in materials and methods. Cells were then probed for
LDLR expression using mock cells as control. It was observed that
in presence of 10 and 25 nM LNA ASO the cell surface expression
of LDLR was increased by ,50% as compared to control
(Figure 5).
The FACS results revealed that the significant (P,0.01) knock-
down of PCSK9 mRNA levels associated with the presence of the
LNA ASO, resulting in the reduction of PCSK9 protein amounts,
also leads to a 1.5-fold increase in the cell surface protein
expression of the LDLR.
Cytotoxicity of LNA ASO
To assess the potential cytotoxicity of the LNA ASO used in this
study, cell viability was determined. Cell confluency, a qualitative
measure of cell viability based upon cell coverage on the well
surface, as judged by microscopy, indicated no visible toxicity at
the concentrations of LNA used for transfection. To obtain a more
quantitative measure of cell viability, we assayed cell metabolism
Figure 4. Reduction in the levels PCSK9 protein by LNA ASO is accompanied by an increase in LDLR protein expression. HepG2 cells
were transfected with 5, 10 and 25 nM LNA ASO (lanes 2–4). For mock, only water was used instead of LNA solution (lane 1). (A) 72h later, cell lysates
were analyzed by Western blot for endogenous levels of human PCSK9 along with LDLR protein levels. The protein b-actin was used as a loading
control. (B) Western blot analysis of overnight conditioned media of LNA ASO-transfected HepG2 cells, reflecting the levels of secreted PCSK9.
doi:10.1371/journal.pone.0010682.g004
PCSK9 Silencing In Vivo
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10682activity using Alamar blue [36,37]. LNA ASO was found to be
almost non toxic, with more than 85% of the cells being viable
after 48h of incubation with 10 and 25 nM LNA ASO (Figure 6).
In vivo effect and dosing
In order to determine potency and efficacy of the 13-mer the
LNA ASO in vivo, female NMRI mice were given a single i.v.
injection of 5–40 mg/kg, sacrificed 24h post injection. Hepatic
PCSK9 mRNA expression was found to be significantly reduced
by the LNA ASO compared to saline (P,0.01 for all dose levels)
dose-dependently and as expected with no effect on LDLR mRNA
(Figures 7A and 7B). However, a concomitant increase in the level
of hepatic LDLR protein by 2–3 fold was observed in the high
dose groups (20 and 40 mg/kg) compared to the control treated
with saline (P,0.01 for both doses; Figure 7C). The estimated
ED50 was ,9 mg/kg and the estimated maximum response
approached 95% reduction of PCSK9 mRNA (GraphPad Prism,
non-linear fit, R
2=0.81; Figure 7A). The mechanistic connection
was confirmed in mice and the reduction of PCSK9 mRNA
resulted in an increase in LDLR protein but not LDLR mRNA
levels, as also seen in vitro (Figure 4).
It has previously been described [28] that knockdown of PCSK9
mRNA up-regulated the apoB editing enzyme Apobec-1 by 2–3
fold. In the present study the mRNA levels of the LDLR and
Apobec-1 were not influenced by treatment with the LNA ASO at
any of the dose levels (Figure 7B), in agreement with the results
observed in Pcsk9 knockout mice [14]. Finally, there were no
elevations in hepatic alanine aminotransferase (ALT), indicating
no immediate hepatocellular injury by the LNA ASO (data not
shown).
Duration of action in vivo
With the objective to determine the duration of action, mice
were treated with a single i.v. injection of 20 mg/kg and sacrificed
at post injection days 1, 3, 5, 8, 16 and 32. The livers were
analyzed for PCSK9 mRNA and LDLR protein (Figures 8A and
8B). At 24h post injection the PCSK9 mRNA was reduced by
Figure 5. Cell surface expression of LDLR in LNA ASO treated
HepG2 cells. Cells were transfected with 10 and 25 nM LNA ASO, and
after 72 h FACS analysis was done to evaluate surface expression of
LDLR using anti human LDLR as primary antibody and a suitable
secondary antibody labeled with alexa 647.
doi:10.1371/journal.pone.0010682.g005
Figure 6. Cell viability measurement. HepG2 cells were transfected
for 4h with water for mock or 10 and 25 nM LNA ASO using
Lipofectamine 2000 and incubated for 48h. The cells were then treated
with Alamar blue reagent and analyzed on an Elisa plate reader for cell
viability.
doi:10.1371/journal.pone.0010682.g006
Figure 7. Dose-dependent PCSK9 mRNA response in mice after
a single i.v. injection at 5–40 mg/kg. (A) Dose-response curve of
PCSK9 mRNA levels in the liver (mean and SEM, n=5), where the ED50
estimation is 9 mg/kg and maximum effect 95% reduction of the PCSK9
mRNA. (B) There is no change in mRNA levels of LDLR or Apobec. (C)
LDLR protein is up-regulated 2–3 fold in the treated animals in the high
dose groups. (Mean and SEM, n=4–5).
doi:10.1371/journal.pone.0010682.g007
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The reduction was significant up to day 16 (P,0.001). The
reduction in PCSK9 mRNA levels resulted in an immediate and
significant up-regulation by 2.5–3 fold of the hepatic LDLR
protein, an effect that lasted for at least 8 days (P,0.05) and was
no significantly increased at day 16 (Figure 8).
Effect of repeated low dose in vivo
The data for the dose-response and duration of action studies
indicated that dosing 5–10 mg/kg once weekly would be sufficient
to give a continuous reduction in hepatic PCSK9 mRNA
expression followed by an up-regulation of hepatic LDLR protein.
To validate this hypothesis and the therapeutic potential of the
LNA ASO, a multiple dose study with weekly dosing of 5 mg/kg of
the 13-mer LNA antisense oligonucleotide was conducted. Mice
were administered i.v. 5 mg/kg/week, sacrificed on days 21, 35
and 49 (each time point occurring one week after the last dose), the
livers were analyzed for PCSK9 mRNA expression and LDLR
protein levels (Figures 9A and 9C). At this dose, PCSK9 mRNA
had reached a significant steady reduction of ,60% below saline
treated animals (P,0.005). While LDLR mRNA levels remained
constant, LDLR protein was up-regulated 2–3 fold on days 21, 35
(P,0.05) and 49 (P=0.052) (Figures 9B and 9C).
Finally, after seven weekly doses and one week after the last
dose, there was no effect on ALT activity (data not shown),
emphasizing the lack of hepatocellular damage even after long
term administration of LNA ASO.
PCSK9 down-regulates the expression of LDLR and thus
directly participates in the aetiology of the hypercholesterolemia
phenotype. Short, single stranded, unformulated LNA oligonucle-
otides hold significant promise as drugs for potent, safe and
selective modulation of therapeutic interesting mRNA and
miRNA targets. In the present work, we have therefore for the
first time used an LNA modified antisense oligonucleotide in order
to lower PCSK9 gene expression, and thus inhibit the intracellular
as well as extracellular pathways of LDLR degradation. We have
also shown that the LNA ASO did not affect the mRNA levels of
LDLR. Taken together, this supports the specificity of the LNA
ASO towards PCSK9. The use of the LNA ASO has thus reduced
the expression of mRNA levels of PCSK9 and this in turn has
Figure 8. Duration of action after a single i.v. injection in mice.
A single injection of 20 mg/kg LNA ASO generated a significant
reduction of PCSK9 mRNA lasting for more than two weeks (A), with
concomitant increase in LDLR protein (B). Levels were normalized at
day 32. (Mean and SEM, n=4–5).
doi:10.1371/journal.pone.0010682.g008
Figure 9. Repeated dosing in mice. Weekly repeated dosing at 5
mg/kg of the LNA ASO led to a stable reduction of PCSK9 mRNA (A),
unchanged levels of LDLR mRNA (B) and 2–3 fold up-regulation of LDLR
protein levels (C) (white bars: Saline, black bars: LNA ASO) (Mean and
SD, n=4–5).
doi:10.1371/journal.pone.0010682.g009
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protein in cell lines being studied.
Both in vitro and in vivo studies presented in this work support the
concept of the use of antisense LNA oligonucleotides for
cholesterol lowering therapy. We are confident that LNA ASO
will open the way towards future animal and clinical trials and
show the therapeutic usefulness of using this PCSK9 silencing
approach, as it has been for other targets.
Supporting Information
Figure S1 QPCR analysis of PCSK9 and LDLR mRNAs in
HepG2 cells transfected by an off-target LNA ASO. HepG2 cells
were transfected with 10 and 25 nM of a non-target control LNA
ASO, and mRNA levels of PCSK9 and LDLR in cell lysates were
then measured by QPCR at 24 or 48h post-transfection. The
levels of mRNAs were normalized to human S14 mRNA.
Found at: doi:10.1371/journal.pone.0010682.s001 (0.02 MB TIF)
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